Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, September 03, 2025 - PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. (“Coya” or the “Company”) (NASDAQ: COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases. Arun Swaminathan, CEO, Coya Therapeutics, Inc. In the...
